12,372 trials
Diagnostic Self Evaluation · Central Nervous System Diseases
Primary: MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" Evaluation — 1.06; 3.30; 1.62…
Diabetes · Diabetes Mellitus, Type 2
Primary: Incidence of Treatment Emergent Adverse Events (AEs) — 361; 331; 345; 321 Events/100 years of patient exposure
Depressive Disorder, Major
Primary: Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5% — 258; 80; 68; 65 participants
Staphylococcal Infection
Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants
Osteoarthritis
Primary: Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain…
Chronic Kidney Disease · Anemia
Primary: Percentage of Participants Undergoing Conversion to Peginesatide Injection — 88 percentage of participants
Essential Hypertension
Primary: Assess the Therapeutic Equivalence of Eprosartan (a New Formulation Containing Only the Active Moiety Eprosartan) With Eprosartan Mesylate (Currently Marketed…
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of Exposure — 1.17; 1.18 score on a scale — p=0.913
Perennial Allergic Rhinitis · PAR
Primary: The Change in Serum Cortisol Area Under the Curve (AUC) From Time 0 to 24 Hours (0-24), Calculated Using a Trapezoidal Rule, From Baseline to the End of the 6 Week…
Attention Deficit/Hyperactivity Disorder
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths. — 208; 2; 0 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16 — -1.73; -0.43 percentage of glycosylated haemoglobin — p=<0.0001
Attention-Deficit/Hyperactivity Disorder
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 13 — -18.527; -24.552 units on a scale…
Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score — -10.9; -9.5; -4.5 Scores on a scale
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants — -5.13; -7.93; -6.05; -9.69…
Herpes Labialis
Primary: Reporting of Adverse Events — 9 participants